Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. It has a collaboration agreement with Thermo Fisher Scientific Inc. for the development of colorectal cancer screening product. The company was founded in 2008 and is based in Mainz, Germany. more
Time Frame | MYNZ | Sector | S&P500 |
---|---|---|---|
1-Week Return | -2.28% | 0.49% | -0.42% |
1-Month Return | -28.67% | -3.1% | -2.2% |
3-Month Return | 1220.99% | -8.59% | 2.38% |
6-Month Return | 949.02% | -4.57% | 5.1% |
1-Year Return | 259.06% | -0.94% | 23.79% |
3-Year Return | -68.7% | 2.88% | 26.66% |
5-Year Return | -83.82% | 35.84% | 81.16% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 281.39K | 493.56K | 577.35K | 529.88K | 895.48K | [{"date":"2019-12-31","value":31.42,"profit":true},{"date":"2020-12-31","value":55.12,"profit":true},{"date":"2021-12-31","value":64.47,"profit":true},{"date":"2022-12-31","value":59.17,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 342.66K | 370.48K | 399.73K | 347.73K | 385.82K | [{"date":"2019-12-31","value":85.72,"profit":true},{"date":"2020-12-31","value":92.68,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":86.99,"profit":true},{"date":"2023-12-31","value":96.52,"profit":true}] |
Gross Profit | (61.27K) | 123.08K | 177.62K | 182.15K | 509.66K | [{"date":"2019-12-31","value":-12.02,"profit":false},{"date":"2020-12-31","value":24.15,"profit":true},{"date":"2021-12-31","value":34.85,"profit":true},{"date":"2022-12-31","value":35.74,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | (21.77%) | 24.94% | 30.77% | 34.38% | 56.91% | [{"date":"2019-12-31","value":-38.26,"profit":false},{"date":"2020-12-31","value":43.82,"profit":true},{"date":"2021-12-31","value":54.05,"profit":true},{"date":"2022-12-31","value":60.4,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 690.21K | 479.39K | 9.56M | 26.36M | 27.15M | [{"date":"2019-12-31","value":2.54,"profit":true},{"date":"2020-12-31","value":1.77,"profit":true},{"date":"2021-12-31","value":35.19,"profit":true},{"date":"2022-12-31","value":97.06,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (921.91K) | (325.81K) | (9.38M) | (26.17M) | (26.64M) | [{"date":"2019-12-31","value":-92190900,"profit":false},{"date":"2020-12-31","value":-32581100,"profit":false},{"date":"2021-12-31","value":-937925900,"profit":false},{"date":"2022-12-31","value":-2617475400,"profit":false},{"date":"2023-12-31","value":-2664468200,"profit":false}] |
Total Non-Operating Income/Expense | (237.08K) | (529.88K) | (2.30M) | (232.62K) | (460.63K) | [{"date":"2019-12-31","value":-23708200,"profit":false},{"date":"2020-12-31","value":-52987600,"profit":false},{"date":"2021-12-31","value":-230466300,"profit":false},{"date":"2022-12-31","value":-23262000,"profit":false},{"date":"2023-12-31","value":-46062600,"profit":false}] |
Pre-Tax Income | (957.05K) | (586.89K) | (11.70M) | (26.39M) | (26.30M) | [{"date":"2019-12-31","value":-95705500,"profit":false},{"date":"2020-12-31","value":-58689500,"profit":false},{"date":"2021-12-31","value":-1169515800,"profit":false},{"date":"2022-12-31","value":-2638733600,"profit":false},{"date":"2023-12-31","value":-2629572700,"profit":false}] |
Income Taxes | 217.71K | 299.28K | 377.12K | 65.39K | 1.92M | [{"date":"2019-12-31","value":11.34,"profit":true},{"date":"2020-12-31","value":15.59,"profit":true},{"date":"2021-12-31","value":19.65,"profit":true},{"date":"2022-12-31","value":3.41,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (1.17M) | (886.18K) | (12.07M) | (26.45M) | (28.22M) | [{"date":"2019-12-31","value":-117476600,"profit":false},{"date":"2020-12-31","value":-88617700,"profit":false},{"date":"2021-12-31","value":-1207228000,"profit":false},{"date":"2022-12-31","value":-2645272500,"profit":false},{"date":"2023-12-31","value":-2821516700,"profit":false}] |
Income From Continuous Operations | (957.05K) | (586.89K) | (11.70M) | (26.39M) | (26.30M) | [{"date":"2019-12-31","value":-95705500,"profit":false},{"date":"2020-12-31","value":-58689500,"profit":false},{"date":"2021-12-31","value":-1169515800,"profit":false},{"date":"2022-12-31","value":-2638733600,"profit":false},{"date":"2023-12-31","value":-2629572700,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (1.17M) | (886.18K) | (12.07M) | (26.45M) | (26.30M) | [{"date":"2019-12-31","value":-117476600,"profit":false},{"date":"2020-12-31","value":-88617700,"profit":false},{"date":"2021-12-31","value":-1207228000,"profit":false},{"date":"2022-12-31","value":-2645272500,"profit":false},{"date":"2023-12-31","value":-2629572700,"profit":false}] |
EPS (Diluted) | - | - | (0.17) | (2.19) | (1.64) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-16.98,"profit":false},{"date":"2022-12-31","value":-219,"profit":false},{"date":"2023-12-31","value":-164,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
MYNZ | |
---|---|
Cash Ratio | 0.77 |
Current Ratio | 0.97 |
Quick Ratio | 0.91 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
MYNZ | |
---|---|
ROA (LTM) | -99.24% |
ROE (LTM) | -4333.71% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
MYNZ | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.79 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.21 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
MYNZ | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 10.37 |
P/B | 1.72 |
Price/FCF | NM |
EV/R | 18.32 |
EV/Ebitda | NM |
Mainz Biomed BV (MYNZ) share price today is $4.28
Yes, Indians can buy shares of Mainz Biomed BV (MYNZ) on Vested. To buy Mainz Biomed BV from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in MYNZ stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Mainz Biomed BV (MYNZ) via the Vested app. You can start investing in Mainz Biomed BV (MYNZ) with a minimum investment of $1.
You can invest in shares of Mainz Biomed BV (MYNZ) via Vested in three simple steps:
The 52-week high price of Mainz Biomed BV (MYNZ) is $7.95. The 52-week low price of Mainz Biomed BV (MYNZ) is $0.18.
The price-to-earnings (P/E) ratio of Mainz Biomed BV (MYNZ) is
The price-to-book (P/B) ratio of Mainz Biomed BV (MYNZ) is 1.72
The dividend yield of Mainz Biomed BV (MYNZ) is 0.00%
The market capitalization of Mainz Biomed BV (MYNZ) is $9.51M
The stock symbol (or ticker) of Mainz Biomed BV is MYNZ